Stock listing

NASDAQ:LYEL Lyell Immunopharma, Inc. Stock

Home listing (NASDAQ) of Lyell Immunopharma, Inc.

Follow Lyell Immunopharma, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:LYEL

$13.80 USD -0.09 (-0.6%)

Close on Nov 20, 2026

Past year -20.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$13.30 – $14.30 USDNov 20, 2026
Volume
171,085 sharesNov 20, 2026
Market cap
$339.3M USDAt the close on Nov 20, 2026 · price × 24.59M shares outstanding
52-week range
$7.20 – $45.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$2.13M USDMedian day 130,954 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Lyell Immunopharma, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:LYEL · Home$13.80 USD-0.09 (-0.6%)171,085$13.36$14.30$13.30$13.89Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:LYEL · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$13.80-0.09-0.6%$13.36$14.30$13.30171,085
$13.89+0.22+1.6%$14.05$14.49$13.50114,134
$13.67-0.98-6.7%$14.58$14.75$13.28175,807
$14.65+0.35+2.4%$14.29$14.93$13.91345,037
$14.30-1.34-8.6%$15.65$15.75$14.20236,617
$15.64-1.22-7.2%$16.70$16.86$15.50130,954
$16.86+0.11+0.7%$16.68$17.60$16.28153,668
$16.75+1.33+8.6%$15.17$17.01$14.92228,147
$15.42+0.56+3.8%$14.91$17.12$14.76409,843
$14.86-0.14-0.9%$15.75$16.08$14.75250,690
$15.00-0.43-2.8%$15.05$16.20$13.69658,413
$15.43+4.66+43.3%$12.09$16.73$12.091,101,234
$10.77-0.11-1.0%$10.92$11.63$10.5878,055
$10.88-0.16-1.4%$11.04$11.40$10.56104,063
$11.04-0.265-2.3%$11.26$11.43$10.79113,300
$11.31+0.375+3.4%$11.00$11.62$11.00149,200
$10.93+0.81+8.0%$10.01$11.03$9.84156,800
$10.12+0.81+8.7%$9.34$10.14$9.26127,900
$9.31-0.08-0.9%$9.35$9.42$9.07585,200
$9.39+0.01+0.1%$9.33$9.445$9.05101,600
$9.38-0.03-0.3%$9.40$9.69$9.2793,200
$9.41-0.29-3.0%$9.65$10.12$9.29118,300
$9.70+0.90+10.2%$8.74$10.01$8.565158,600
$8.80+0.68+8.4%$8.00$9.05$7.92212,900
$8.12-0.07-0.9%$8.24$8.44$7.921195,000
$8.19+0.20+2.5%$8.00$8.44$7.76325,000
$7.99+0.48+6.4%$7.42$8.285$7.195402,200
$7.51-0.76-9.2%$8.27$8.27$7.39187,200
$8.27-0.44-5.1%$8.63$8.69$8.23100,400
$8.71-0.08-0.9%$8.72$9.10$8.615106,800
$8.79+0.23+2.7%$8.49$8.845$8.21194,700
$8.56-0.05-0.6%$8.48$8.95$8.38184,700
$8.61-0.46-5.1%$9.13$9.13$8.585125,000
$9.07-0.19-2.1%$9.27$9.31$8.66129,400
$9.26-0.15-1.6%$9.55$9.56$9.21111,400
$9.41-0.38-3.9%$9.80$9.97$9.36115,200
$9.79+0.16+1.7%$9.61$10.00$9.425153,900
$9.63-0.11-1.1%$9.74$9.74$9.445140,800
$9.74-0.11-1.1%$9.80$9.96$9.60129,000
$9.85-0.27-2.7%$10.16$10.16$9.81108,900
$10.12-0.41-3.9%$10.41$10.76$10.06164,500
$10.53-0.62-5.6%$11.05$11.05$10.32161,500
$11.15+0.22+2.0%$11.09$11.23$10.95211,500
$10.93-0.08-0.7%$11.02$11.18$10.60142,600
$11.01+0.21+1.9%$10.75$11.05$10.53401,100
$10.80+0.025+0.2%$11.01$11.06$10.60133,000
$10.78-0.135-1.2%$10.90$10.98$10.46154,700
$10.91-0.42-3.7%$11.29$11.29$10.55184,100
$11.33-0.63-5.3%$11.97$12.39$11.24104,400
$11.96-0.24-2.0%$12.41$13.00$11.70152,200
$12.20-0.68-5.3%$12.70$12.71$12.04110,900
$12.88-0.65-4.8%$13.52$13.82$12.71101,600
$13.53-0.84-5.8%$14.12$14.13$13.3782,500
$14.37+0.05+0.3%$14.29$14.68$13.9254,100
$14.32-0.635-4.2%$15.11$15.14$14.1979,100
$14.96+0.43+3.0%$14.49$14.97$14.2556,900
$14.53+0.205+1.4%$14.14$14.84$14.0067,000
$14.32-0.21-1.4%$14.51$14.71$14.1462,800
$14.53-0.08-0.5%$14.56$14.78$14.0678,100
$14.61-0.19-1.3%$14.67$15.02$14.3388,400
$14.80-0.69-4.5%$15.34$15.41$14.6187,800
$15.49+0.75+5.1%$15.02$15.68$14.92103,000
$14.74-0.79-5.1%$15.30$15.49$14.4673,200
$15.53+0.18+1.2%$15.54$16.16$15.20104,900
$15.35-0.41-2.6%$15.59$16.02$14.53207,600

Splits

1 split · NASDAQ:LYEL · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
Ticker
NASDAQ:LYEL
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Lyell Immunopharma, Inc. news

Lyell Immunopharma, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
21 in the last 12 months · 92 in all · newest Nov 4, 2026 · oldest 2021
Decks
6 decks · latest September 2026

Where Lyell Immunopharma, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:LYEL · Home listing · This pageNASDAQUnited StatesUSD
BOATS:LYELBOATSUnited StatesUSD

Valuation

EV/sales 13,099× against a median of 45.3×: 8th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$196.5M USD
P/E
Loss
EV/sales
13,099×
EV/EBITDA
Negative EBITDA
Price/book
1.8×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.2×
Beta vs S&P 500
1.51

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Lyell Immunopharma, Inc. · NASDAQ:LYELUS$339.3MUS$196.5Mn/a13,099×n/a1.8×n/a0.2×1.51
AbClon, Inc. · KRX:174900US$348.2MUS$321.1Mn/a80.9×n/a8.8×−328.3%0.0×n/a
Alector, Inc. · NASDAQ:ALECUS$347.6MUS$208.9M8.4×1.2×4.9×3.0×23.9%0.0×1.72
Gongwin Biopharm Holdings Co., Ltd. · TPEX:6617US$347.3MUS$296.6Mn/a232×n/a4.9×−389.6%0.0×n/a
Onconic Therapeutics, Inc. · KRX:476060US$346.5MUS$299.7M19.1×4.9×n/a5.4×29.5%0.0×n/a
Avacta Group PLC · LSE:AVCTUS$337.8MUS$337.2Mn/a2,281×n/a68.5×n/a5.3×n/a
Inovio Pharmaceuticals, Inc. · NASDAQ:INOUS$329.7MUS$7.56Bn/a25,303×3.4×n/an/an/a0.70
Larimar Therapeutics, Inc. · NASDAQ:LRMRUS$328.6MUS$204.7Mn/an/an/a3.2×n/a0.1×1.48
CytoDyn Inc. · OTC:CYDYUS$326.4MUS$345.8Mn/an/an/an/an/an/a0.44
C4 Therapeutics, Inc. · NASDAQ:CCCCUS$325.7MUS$175.5Mn/a5.4×n/a1.4×−282.2%0.2×1.46
Laekna, Inc. · HKEX:2105US$322.8MUS$154.7Mn/a9.7×n/a1.8×−214.9%0.0×n/a
Median of the othersUS$333.7MUS$298.2M13.8×45.3×4.1×4.1×−248.6%0.0×1.46

Forecasts

5 strong buy · 2 buy · 1 sell · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
37.63 USD · Analysts' mean
EPS, year to Dec 2026
-6.69 · 1 analyst
Revenue, year to Dec 2026
14.29K · 7 analysts

Team and board

Officers

OfficerRole
Lynn SeelyPresident and Chief Executive Officer
Smital ShahChief Financial and Business Officer
Stephen HillChief Operating Officer
Mark MeltzGeneral Counsel and Corporate Secretary
Ellen RoseSenior Vice President, Communications and Investor Relations
Pablo FentonAssociate Director, Investor Relations and Corporate Communications
Pablo FentonAssociateDirector, Investor Relations and Corporate
Bryan SelbySenior Vice President, Clinical Development Operations
Peter A. PrietoSenior Vice President, Medical Affairs
Ann TomlinChief Human Resource Officer
Gary LeeChief Scientific Officer
Jarrad AguirreChief Medical Officer
Rick KlausnerFounder & Chairman of the Board

Board

DirectorRole
Rick KlausnerFounder & Chairman of the Board
Catherine FriedmanDirector
Elizabeth NabelDirector
Mark J. BachledaDirector
Otis BrawleyDirector
Sumant RamachandraDirector
William RieflinDirector

Events

QuarterResultsShare move
Q3 2026Nov 4, 2026 · After close−2.8%
Q2 2026Aug 6, 2026 · After close+3.5%
Q1 2026May 6, 2026 · After close−3.8%
Q4 2025Mar 13, 2026−14.7%
Q3 2025Nov 12, 2025 · After close−1.3%
Q2 2025Aug 12, 2025 · After close+2.5%
Q1 2025May 13, 2025 · After close−3.7%
Q4 2024Mar 12, 2025−9.0%
Q3 2024Nov 7, 2024 · After close0.0%
Q2 2024Aug 7, 2024 · After close+6.4%
All 20 quarters
QuarterResultsShare move
Q1 2024May 6, 2024+7.6%
Q4 2023Feb 28, 2024 · After close+2.8%
Q3 2023Nov 7, 2023 · After close+4.4%
Q2 2023Aug 8, 2023 · After close−0.4%
Q1 2023May 4, 2023 · After close+2.5%
Q4 2022Feb 28, 2023 · After close+11.6%
Q3 2022Nov 8, 2022 · After close−18.6%
Q2 2022Aug 4, 2022 · After close+9.3%
Q1 2022May 10, 2022 · After close−11.0%
Q4 2021Mar 29, 2022 · After close+3.3%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck51 slidesSeptember 2026
American Society of Hematology (ASH) 2025Conference21 slidesDec 7, 2025
American Society of Hematology (ASH) 2025Conference13 slidesDec 7, 2025
International Conference on Malignant Lymphoma (ICML) 2025Conference11 slidesJun 18, 2025
Technical Presentation (June 2024)Technical37 slidesJun 26, 2024
Investor Presentation (September 2023)Investor deck35 slidesSep 11, 2023

Open Decks

Financings

RaiseDate
Private placement of private placement
Update: US$80M · US$10.77 a share · Goldman Sachs +1
Dealers: Goldman Sachs, Leerink Partners
Buyers: ARCH Venture Partners; Adage Capital Management LP; Caligan Partners LP; RTW Investments
Use of proceeds: Extend cash runway into 2028, beyond the expected ronde-cel BLA submission and updated LYL273 clinical data
Nov 4, 2026
Private placement of common stock and/or pre-funded warrants
Announced: up to US$100M · US$13.32 a share
Use of proceeds: Fund two pivotal-stage clinical trials of LYL314 and working capital for other general corporate purposes
Jul 25, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$17.00 a share on Jun 16, 2021.

Price
US$17.00 a share
Shares offered
25,000,000 shares of common stock
Offering size
US$425 million
Underwriters' option
Up to 3,750,000 more shares
Underwriters
Goldman Sachs & Co. LLC, BofA Securities, J.P. Morgan, Morgan Stanley · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceApr 12, 2021
Filed publiclyMay 25, 2021
Amended onceJun 9, 2021
Shares registered with an exchangeJun 14, 2021
Declared effective by the SECJun 16, 2021
Final prospectus, with the priceJun 21, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Jun 21, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue36.0K61.0K130.0K84.7M10.7M7.76M657.0K
Cost of revenue11.5M20.3M16.5M14.5M7.47M
Gross profit-11.5M61.0K130.0K84.7M10.7M7.76M657.0K
Research and development158.7M171.6M182.9M159.2M138.7M182.2M63.6M
Selling, general and administrative45.1M52.0M67.0M117.3M89.1M46.9M39.2M
Operating income-269.4M-358.8M-247.0M-187.1M-214.8M-211.9M-102.1M
Depreciation and amortization11.5M19.6M20.3M18.0M13.6M4.29M1.26M
EBITDA-257.9M-339.1M-226.8M-169.0M-201.2M-207.6M-100.8M
Interest expense1.17M5.94M0
Income before tax-274.4M-343.0M-234.6M-183.1M-250.2M-204.5M-129.4M
Income tax0-10.5M-178.4M35.3M-5.94M-8.12M
Net income-274.4M-343.0M-234.6M-183.1M-250.2M-204.5M-129.4M
Earnings per share, basic-16.06-26.23-18.70-0.74-1.84-15.69-24.04
Earnings per share, diluted-16.06-26.23-18.70-0.74-1.84-15.69-24.04

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents60.2M105.6M145.6M123.6M293.8M140.4M96.7M
Short-term investments187.0M264.9M400.6M516.6M321.0M472.2M339.4M
Current assets260.9M379.6M554.7M651.3M626.3M617.5M440.3M
Property, plant and equipment34.8M48.2M102.7M123.0M120.1M77.0M43.7M
Total assets340.1M490.9M750.0M937.6M1.13B908.3M555.6M
Accounts payable2.89M5.37M4.82M3.92M3.21M9.40M2.84M
Current liabilities49.4M53.8M34.5M37.0M46.7M49.3M22.0M
Total debt51.0M59.0M63.2M67.7M67.8M54.6M27.5M
Total liabilities91.8M108.0M95.1M104.3M197.6M189.8M147.6M
Shareholders' equity248.2M382.8M655.0M833.3M929.8M-292.5M-111.1M
Shares outstanding21.3M14.7M254.0M249.6M242.7M15.6M249.6M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-150.0M-162.4M-163.7M-169.6M-126.2M-160.9M39.5M
Capital spending-780.0K-464.0K-2.69M-24.3M-65.5M-51.5M-16.0M
Free cash flow-150.8M-162.9M-166.4M-193.8M-191.8M-212.4M23.4M
Cash from investing54.1M122.4M184.0M-11.5M-121.6M-273.5M-422.4M
Cash from financing50.4M1.33M1.74M10.6M401.2M476.8M351.2M
Share buybacks36.0M-457.0K00-11.8M-185.0K
Change in cash-45.5M-38.6M22.1M-170.5M153.4M42.4M-31.8M

Open Financials

Filings

FilingDateTypeFiled with
S-3 · Registration statementNov 13, 2026Offer documentSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 10, 2026Big-stake noticeSEC
4 · Change in ownershipNov 5, 2026Insider tradeSEC
4 · Change in ownershipNov 5, 2026Insider tradeSEC
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
8-K · Current reportNov 4, 2026ResultsSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportNov 4, 2026FinancingSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
4 · Change in ownershipSep 10, 2026Insider tradeSEC
4 · Change in ownershipSep 10, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 10, 2026Insider tradeSEC
8-K · Current reportSep 10, 2026Current reportSEC
4 · Change in ownershipAug 25, 2026Insider tradeSEC
4 · Change in ownershipAug 25, 2026Insider tradeSEC
4 · Change in ownershipAug 25, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
4 · Change in ownershipJul 27, 2026Insider tradeSEC
4 · Change in ownershipJul 27, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveJul 22, 2026Other filingsSEC
4 · Change in ownershipJul 20, 2026Insider tradeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
CORRESP · Letter to the SECJul 17, 2026Other filingsSEC
UPLOAD · Letter from the SECJul 16, 2026Other filingsSEC
S-3 · Registration statementJul 13, 2026Offer documentSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJun 18, 2026Big-stake noticeSEC
3 · Initial statement of ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
8-K · Current reportJun 15, 2026Meeting outcomeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 11, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 8, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 6, 2026Quarterly reportSEC
8-K · Current reportMay 6, 2026ResultsSEC
ARS · Annual report to shareholdersApr 24, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2026Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeApr 21, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveApr 15, 2026Other filingsSEC
CORRESP · Letter to the SECApr 13, 2026Other filingsSEC
UPLOAD · Letter from the SECApr 8, 2026Other filingsSEC
S-3 · Registration statementApr 3, 2026Offer documentSEC
4 · Change in ownershipMar 16, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 16, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMar 12, 2026Offer documentSEC
10-K · Annual reportMar 12, 2026Annual reportSEC
8-K · Current reportMar 12, 2026ResultsSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
8-K · Current reportMar 9, 2026Management or board changeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
424B5 · ProspectusDec 18, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 16, 2025Other filingsSEC
CORRESP · Letter to the SECDec 11, 2025Other filingsSEC
8-K · Current reportDec 8, 2025Current reportSEC
S-3 · Registration statementDec 5, 2025Offer documentSEC
8-K · Current reportDec 5, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 13, 2025Big-stake noticeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 12, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
3 · Initial statement of ownershipNov 10, 2025Insider tradeSEC
8-K · Current reportNov 10, 2025Material contractSEC
8-K · Current reportNov 3, 2025Management or board changeSEC
4 · Change in ownershipOct 29, 2025Insider tradeSEC
4 · Change in ownershipOct 29, 2025Insider tradeSEC
4 · Change in ownershipOct 29, 2025Insider tradeSEC
8-K · Current reportSep 16, 2025Management or board changeSEC
4 · Change in ownershipAug 22, 2025Insider tradeSEC
4 · Change in ownershipAug 22, 2025Insider tradeSEC
4 · Change in ownershipAug 22, 2025Insider tradeSEC
4 · Change in ownershipAug 22, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeAug 19, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveAug 18, 2025Other filingsSEC
4 · Change in ownershipAug 13, 2025Insider tradeSEC
4 · Change in ownershipAug 13, 2025Insider tradeSEC
4 · Change in ownershipAug 13, 2025Insider tradeSEC
4 · Change in ownershipAug 13, 2025Insider tradeSEC
CORRESP · Letter to the SECAug 13, 2025Other filingsSEC
UPLOAD · Letter from the SECAug 13, 2025Other filingsSEC
S-3 · Registration statementAug 12, 2025Offer documentSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeAug 1, 2025Big-stake noticeSEC
424B5 · ProspectusJul 31, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveJul 31, 2025Other filingsSEC
4 · Change in ownershipJul 29, 2025Insider tradeSEC
3 · Initial statement of ownershipJul 29, 2025Insider tradeSEC
CORRESP · Letter to the SECJul 28, 2025Other filingsSEC
8-K · Current reportJul 25, 2025Material contractSEC
UPLOAD · Letter from the SECJul 23, 2025Other filingsSEC
S-3 · Registration statementJul 18, 2025Offer documentSEC
8-K · Current reportJun 26, 2025FinancingSEC
8-K · Current reportJun 17, 2025Current reportSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 11, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 11, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 11, 2025Insider tradeSEC
8-K · Current reportJun 9, 2025Management or board changeSEC
8-K · Current reportMay 28, 2025Current reportSEC
8-K · Current reportMay 21, 2025Meeting outcomeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
8-K · Current reportMay 13, 2025ResultsSEC
ARS · Annual report to shareholdersApr 21, 2025Annual reportSEC
DEF 14A · Proxy statementApr 21, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 10, 2025Meeting noticeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
8-K · Current reportApr 1, 2025Management or board changeSEC
4 · Change in ownershipMar 25, 2025Insider tradeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
S-8 · Registration statement for employee plansMar 11, 2025Offer documentSEC
10-K · Annual reportMar 11, 2025Annual reportSEC
8-K · Current reportMar 11, 2025ResultsSEC
4 · Change in ownershipFeb 26, 2025Insider tradeSEC
4 · Change in ownershipFeb 26, 2025Insider tradeSEC
4 · Change in ownershipFeb 26, 2025Insider tradeSEC
4 · Change in ownershipFeb 26, 2025Insider tradeSEC
4 · Change in ownershipFeb 26, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2025Big-stake noticeSEC
8-K · Current reportJan 24, 2025Current reportSEC
8-K/A · Current report, amendedJan 10, 2025Current reportSEC
8-K · Current reportDec 9, 2024Current reportSEC
424B5 · ProspectusDec 9, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 6, 2024Other filingsSEC
CORRESP · Letter to the SECDec 3, 2024Other filingsSEC
UPLOAD · Letter from the SECDec 3, 2024Other filingsSEC
S-3 · Registration statementNov 29, 2024Offer documentSEC
8-K · Current reportNov 26, 2024Management or board changeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
4 · Change in ownershipNov 1, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 1, 2024Insider tradeSEC
SC 13G · Big-stake noticeOct 31, 2024Big-stake noticeSEC
8-K · Current reportOct 31, 2024Acquisition or disposalSEC
8-K · Current reportOct 24, 2024Material contractSEC
10-Q · Quarterly reportAug 7, 2024Quarterly reportSEC
8-K · Current reportAug 7, 2024ResultsSEC
8-K · Current reportJun 26, 2024Current reportSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
8-K · Current reportJun 14, 2024Meeting outcomeSEC
424B5 · ProspectusMay 6, 2024Offer documentSEC
10-Q · Quarterly reportMay 6, 2024Quarterly reportSEC

This page holds 200 of 365 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Lyell Immunopharma, Inc.’s releases · as of Oct 30, 2026

Common shares
24,585,565
Fully diluted
24,585,565

Fully diluted

LineSharesAs of
Common shares24,585,565Oct 30, 2026

Share count over time

CountShares
Oct 30, 202624,585,565

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
ARCH Venture Management, LLC3.25M13.2%US$31.8MSep 30, 2026
GSK plc1.51M6.2%US$14.8MSep 30, 2026
Vanguard916K3.7%US$8.97MSep 30, 2026
BlackRock799K3.3%US$7.82MSep 30, 2026
Orland Properties Ltd755K3.1%US$7.39MSep 30, 2026
Almitas Capital LLC448K1.8%US$4.39MSep 30, 2026
AQR Capital Management LLC346K1.4%US$3.39MSep 30, 2026
venBio Partners LLC338K1.4%US$3.31MSep 30, 2026
Alphabet Inc.293K1.2%US$2.87MSep 30, 2026
Opaleye Management Inc.291K1.2%US$2.85MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Geode Capital275K1.1%US$2.69MSep 30, 2026
State Street192K0.78%US$1.88MSep 30, 2026
Renaissance Technologies189K0.77%US$1.85MSep 30, 2026
Two Sigma168K0.68%US$1.65MSep 30, 2026
HSG Holding Ltd152K0.62%US$1.49MSep 30, 2026
Qube Research & Technologies Ltd142K0.58%US$1.39MSep 30, 2026
Millennium141K0.57%US$1.38MSep 30, 2026
Goldman Sachs109K0.44%US$1.06MSep 30, 2026
Citadel107K0.43%US$1.05MSep 30, 2026
Northern Trust98,6620.40%US$966KSep 30, 2026
Acadian Asset Management LLC97,9510.40%US$953KSep 30, 2026
Schwab93,1490.38%US$912KSep 30, 2026
Morgan Stanley89,4230.36%US$875KSep 30, 2026
MIC Capital Management UK LLP87,0280.35%US$852KSep 30, 2026
Parkman Healthcare Partners LLC85,7580.35%US$840KSep 30, 2026
UBS84,6750.34%US$829KSep 30, 2026
Trexquant Investment LP67,1750.27%US$658KSep 30, 2026
XTX Topco Ltd57,9030.24%US$567KSep 30, 2026
Point72 Asset Management, L.P.56,9920.23%US$558KSep 30, 2026
JPMorgan49,6080.20%US$478KSep 30, 2026
Dimensional46,4340.19%US$454KSep 30, 2026
Ikarian Capital, LLC41,0810.17%US$402KSep 30, 2026
Squarepoint Ops LLC39,0440.16%US$382KSep 30, 2026
Schonfeld Strategic Advisors LLC38,9560.16%US$381KSep 30, 2026
Gsa Capital Partners LLP38,4000.16%US$376KSep 30, 2026
Jane Street36,4520.15%US$357KSep 30, 2026
Verdad Advisers, LP35,0870.14%US$344KSep 30, 2026
T. Rowe Price30,6570.12%US$301KSep 30, 2026
CPP Investments29,4110.12%US$288KSep 30, 2026
Rhumbline Advisers25,7870.10%US$252KSep 30, 2026
BNP Paribas25,4110.10%US$249KSep 30, 2026
Empowered Funds, LLC25,1710.10%US$246KSep 30, 2026
Bridgeway Capital Management, LLC25,1710.10%US$246KSep 30, 2026
BNY24,8180.10%US$243KSep 30, 2026
Creative Planning24,6710.10%US$242KSep 30, 2026
American Century24,4300.10%US$239KSep 30, 2026
Jump Financial, LLC21,4000.09%US$210KSep 30, 2026
Susquehanna21,3720.09%US$209KSep 30, 2026
Clearstead Advisors, LLC19,9820.08%US$196KSep 30, 2026
HSBC19,8400.08%US$192KSep 30, 2026

This page holds 50 of 99 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund604K2.5%US$8.49MJun 30, 2026
iShares Russell 2000 ETF227K0.92%US$3.19MJun 30, 2026
Vanguard Extended Market Index Fund164K0.67%US$2.3MJun 30, 2026
Fidelity Small Cap Index Fund104K0.42%US$1.34MJul 31, 2026
iShares Russell 2000 Value ETF89,6740.36%US$1.26MJun 30, 2026
Fidelity Extended Market Index Fund67,7140.28%US$1.17MMay 31, 2026
Schwab U.S. Small-Cap ETF67,4480.27%US$1.17MMay 31, 2026
iShares Biotechnology ETF54,0710.22%US$760KJun 30, 2026
iShares Micro-Cap ETF31,5810.13%US$444KJun 30, 2026
Small Cap Value Fund28,3500.12%US$398KJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Fidelity Total Market Index Fund25,8300.11%US$448KMay 31, 2026
Avantis U.S. Small Cap Equity ETF23,0050.09%US$399KMay 31, 2026
Schwab Small-Cap Index Fund22,9300.09%US$297KJul 31, 2026
Vanguard Health Care Index Fund22,9190.09%US$397KMay 31, 2026
Fidelity Series Total Market Index Fund21,4670.09%US$372KMay 31, 2026
Ultra-Small Company Market Fund18,0000.07%US$253KJun 30, 2026
Master Small Cap Index Series17,5890.07%US$247KJun 30, 2026
Fidelity Nasdaq Composite Index Fund13,9280.06%US$241KMay 31, 2026
Fidelity Small Cap Value Index Fund13,3160.05%US$187KJun 30, 2026
Nuveen Small Cap Blend Index Fund12,5950.05%US$163KJul 31, 2026
U.S. Micro Cap Portfolio11,4210.05%US$148KJul 31, 2026
Allspring Disciplined Small Cap Fund10,8100.04%US$152KJun 30, 2026
U.S. Small Cap Portfolio10,5960.04%US$137KJul 31, 2026
EQ/2000 Managed Volatility Portfolio10,1720.04%US$143KJun 30, 2026
Vanguard Balanced Index Fund9,3200.04%US$131KJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund9,2380.04%US$130KJun 30, 2026
Schwab U.S. Broad Market ETF9,1010.04%US$158KMay 31, 2026
Invesco RAFI US 1500 Small-Mid ETF9,0290.04%US$117KJul 31, 2026
Schwab Total Stock Market Index Fund8,1430.03%US$105KJul 31, 2026
Fidelity ZERO Total Market Index Fund7,4280.03%US$96,118Jul 31, 2026
LVIP State Street Small-Cap Index Fund7,3000.03%US$103KJun 30, 2026
T. Rowe Price Extended Equity Market Index Fund6,5570.03%US$92,126Jun 30, 2026
Fidelity ZERO Extended Market Index Fund5,1370.02%US$66,473Jul 31, 2026
Small Cap Index Fund4,9430.02%US$69,449Jun 30, 2026
Global X Russell 2000 ETF4,4740.02%US$57,894Jul 31, 2026
ATM Small Cap Managed Volatility Portfolio3,6180.01%US$50,833Jun 30, 2026
Goldman Sachs Absolute Return Tracker Fund2,9230.01%US$41,068Jun 30, 2026
Small-Cap Index Portfolio2,7160.01%US$38,160Jun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio2,5000.01%US$35,125Jun 30, 2026
Fidelity Flex Small Cap Index Fund2,355<0.01%US$30,474Jul 31, 2026
JNL/DFA U.S. Small Cap Fund2,211<0.01%US$31,065Jun 30, 2026
NVIT Small Cap Index Fund2,138<0.01%US$30,039Jun 30, 2026
1290 VT Micro Cap Portfolio2,122<0.01%US$29,814Jun 30, 2026
Dimensional US Core Equity 1 ETF1,961<0.01%US$25,375Jul 31, 2026
U.S. Vector Equity Portfolio1,896<0.01%US$24,534Jul 31, 2026
Dimensional U.S. Small Cap ETF1,736<0.01%US$22,464Jul 31, 2026
EQ/Small Company Index Portfolio1,510<0.01%US$21,216Jun 30, 2026
EQ/AB Small Cap Growth Portfolio1,510<0.01%US$21,216Jun 30, 2026
1290 VT Small Cap Value Portfolio1,488<0.01%US$20,906Jun 30, 2026
DWS Small Cap Index VIP1,465<0.01%US$20,583Jun 30, 2026

This page holds 50 of 84 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Seely Lynn
Director, Officer: President and CEO
Sale545USD 15.93US$8,682Nov 10, 2026
Hill Stephen J.
Officer: Chief Operating Officer
Sale88USD 15.93US$1,402Nov 10, 2026
Lee Gary K.
Officer: Chief Scientific Officer
Sale129USD 15.93US$2,055Nov 10, 2026
Bulis Veronica Sanchez
Officer: VP, Corporate Controller
Sale416USD 15.93US$6,627Nov 10, 2026
ARCH Venture Fund XIII, L.P.
10% owner
Buy2,321,262USD 10.77US$25MNov 4, 2026
ARCH Venture Partners IX, LLC
10% owner
Buy2,321,262USD 10.77US$25MNov 4, 2026
Aguirre Jarrad Mattieu
Officer: Chief Medical Officer
Sale422USD 8.63US$3,642Oct 12, 2026
Shook David
Officer: Chief Medical Officer
Sale500USD 12.70US$6,350Sep 10, 2026
Seely Lynn
Director, Officer: President and CEO
Sale9,589USD 15.54US$149KAug 21, 2026
Hill Stephen J.
Officer: Chief Operating Officer
Sale989USD 15.54US$15,369Aug 21, 2026
All 22 trades
TradeTradeSharesPriceValueDate
Lee Gary K.
Officer: Chief Scientific Officer
Sale1,457USD 15.54US$22,642Aug 21, 2026
Seely Lynn
Director, Officer: President and CEO
Sale390USD 14.34US$5,593Aug 10, 2026
Hill Stephen J.
Officer: Chief Operating Officer
Sale89USD 14.34US$1,276Aug 10, 2026
Lee Gary K.
Officer: Chief Scientific Officer
Sale131USD 14.34US$1,879Aug 10, 2026
Bulis Veronica Sanchez
Officer: VP, Corporate Controller
Sale621USD 14.34US$8,905Aug 10, 2026
Innovative Cellular Therapeutics Holdings Ltd
10% owner
Sale10USD 13.70US$137Jul 17, 2026
Innovative Cellular Therapeutics Holdings Ltd
10% owner
Sale10USD 13.73US$137Jul 16, 2026
Shook David
Officer: Chief Medical Officer
Sale1,977USD 12.64US$24,989Jun 10, 2026
Seely Lynn
Director, Officer: President and CEO
Sale388USD 18.91US$7,337May 11, 2026
Hill Stephen J.
Officer: Chief Operating Officer
Sale89USD 18.92US$1,684May 11, 2026
Lee Gary K.
Officer: Chief Scientific Officer
Sale130USD 18.92US$2,460May 11, 2026
Bulis Veronica Sanchez
Officer: VP, Corporate Controller
Sale217USD 18.91US$4,103May 11, 2026

Big stakes

StakeStakeSharesDateFiling
ARCH Venture Fund IX, L.P.17.40%5.57MNov 4, 2026Schedule 13G
Innovative Cellular Therapeutics Holdings Limited12.30%3MMay 18, 2026Schedule 13G
EULER FUND, L.P.6.71%1.43MMar 6, 2026Schedule 13G
Explore Investments LLC6.60%1.53MMar 31, 2026Schedule 13G
Gates Frontier, LLC5.60%1.04MJul 25, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Heather Turner
Other companies: Avalyn Pharma Inc. (Director · Since at least Apr 29, 2026); LB Pharmaceuticals Inc (Chief Executive Officer, Director · Since at least Sep 10, 2025); Terns Pharmaceuticals, Inc. (Director · Since at least Nov 18, 2024); Sangamo Therapeutics, Inc. (EVP, General Counsel & Sec. · Feb 12, 2018 – Feb 25, 2019 · Past); Atara Biotherapeutics, Inc. (Former EVP, GC & Sec. · Feb 6, 2018 – Feb 9, 2018 · Past)
Chief General Counsel · Jun 16, 2021 – Mar 16, 2022 · Past
Charles Newton
Other companies: Keros Therapeutics, Inc. (Director · Since at least Feb 26, 2026); Novavax, Inc. (Director · Since at least Apr 25, 2025); Coherus Oncology, Inc. (Director · Since at least May 4, 2022); 2Seventy Bio Inc (Director · Mar 20, 2024 – May 13, 2025 · Past)
Chief Financial Officer · Since at least Jun 16, 2021
Hans Bishop
Other companies: Sana Biotechnology, Inc. (Chairman · Since at least Feb 3, 2021); Celgene Corporation (Director · Apr 18, 2018 – Nov 20, 2019 · Past); Agilent Technologies, Inc. (Director · Jul 18, 2017 – Mar 15, 2024 · Past); Juno Therapeutics Inc (CEO & President, Director · Jun 9, 2016 – Mar 5, 2018 · Past)
Director · Jun 16, 2021 – Jun 14, 2024 · Past
Otis W. Brawley
Other companies: Agilent Technologies, Inc. (Director · Since at least Nov 17, 2021); Incyte Corporation (Director · Since at least Sep 27, 2021); PDS Biotechnology Corporation (Director · Since at least Nov 3, 2020); Theragenics Corp (Director · May 9, 2006 – May 18, 2007 · Past)
Director · Since at least Jun 16, 2021
Cathy Friedman
Other companies: Revolution Healthcare Acquisition Corp (Director · Mar 17, 2021 – Mar 17, 2021 · Past); Seer, Inc. (Director · Dec 3, 2020 – Jun 14, 2023 · Past); Radius Health, Inc. (Director · Feb 20, 2020 – Aug 15, 2022 · Past)
Director · Since at least Jun 16, 2021
Elizabeth Nabel
Other companies: Moderna, Inc. (Director · Since at least Dec 7, 2018); Medtronic plc. (Director · Since at least Sep 16, 2014); Accolade, Inc. (Director · Jun 2, 2021 – Apr 8, 2025 · Past)
Director · Since at least Jun 16, 2021
Lynn Seely
Other companies: AbCellera Biologics Inc. (Director · Since at least Jun 30, 2026); Blueprint Medicines Corp (Director · Since at least Jun 19, 2019); Myovant Sciences Ltd (Principal Executive Officer, Director · Apr 5, 2019 – Apr 3, 2020 · Past)
President and CEO, Director · Since at least Jun 16, 2021
Matthew Lang
Other companies: Structure Therapeutics, Inc. (COO & GC · Since at least Apr 15, 2026); Metsera, Inc. (CHIEF LEGAL OFFICER · Since at least Apr 28, 2025); Myovant Sciences Ltd (General Counsel & Corp. Secy. · Apr 5, 2019 – Mar 10, 2023 · Past)
Chief Business Officer · Jul 1, 2023 – Feb 10, 2025 · Past
William Rieflin
Other companies: RAPT Therapeutics Inc (Director · Oct 30, 2019 – May 22, 2024 · Past); NGM Biopharmaceuticals Inc (Director · Apr 3, 2019 – Apr 5, 2024 · Past); XenoPort Inc (Director · May 17, 2016 – Jul 5, 2016 · Past)
Director · Since at least Jun 16, 2021
Mark Meltz
Other companies: Kinnate Biopharma Inc (COO GENERAL COUNSEL SECRETARY · Dec 2, 2020 – Apr 3, 2024 · Past); Audentes Therapeutics Inc (SVP, General Counsel · Mar 28, 2019 – Jan 15, 2020 · Past)
General Counsel and Corporate Secretary · Since at least Jun 9, 2025
All 28 people
PersonSeat
Smital Shah
Other companies: LENZ Therapeutics, Inc. (Director · Apr 15, 2021 – Jul 19, 2023 · Past); Pliant Therapeutics, Inc. (Director · Jun 2, 2020 – Jun 13, 2024 · Past)
Chief Financial and Business Officer · Since at least Mar 9, 2026
David Shook
Other companies: Nkarta, Inc. (See Remarks · Jan 1, 2023 – Jan 15, 2025 · Past)
Chief Medical Officer · Since at least Jun 9, 2025
Ellen Rose
Other companies: LB Pharmaceuticals Inc (Senior Vice President, Corporate Affairs · Since at least Oct 15, 2026)
Senior Vice President, Communications and Investor Relations · Since at least Dec 7, 2025
Mark J. Bachleda
Other companies: Galera Therapeutics, Inc. (Chief Commercial Officer · Oct 8, 2021 – Mar 16, 2023 · Past)
Director · Since at least Jun 9, 2025
Richard Klausner
Other companies: Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026)
Director · Since at least Jun 8, 2021
Rick Klausner
Other companies: Parabilis Medicines, Inc. (Founder and Chief Scientist Altos Labs, Inc. · Since at least Nov 4, 2026)
Founder & Chairman of the Board · Since at least Jun 9, 2025
Ann TomlinChief Human Resource Officer · Since at least Nov 5, 2026
Bryan SelbySenior Vice President, Clinical Development Operations · Since at least Nov 5, 2026
Catherine FriedmanDirector · Since at least Nov 5, 2026
Elizabeth HomansChief Executive Officer, Director · Jun 16, 2021 – Mar 16, 2022 · Past
Gary LeeChief Scientific Officer · Since at least Nov 16, 2023
Jarrad AguirreChief Medical Officer · Since at least Jun 9, 2025
Pablo FentonAssociate Director, Investor Relations and Corporate Communications · Since at least Aug 6, 2026
Pablo FentonAssociateDirector, Investor Relations and Corporate · Since at least Jun 4, 2026
Peter A. PrietoSenior Vice President, Medical Affairs · Since at least Nov 5, 2026
Stephen HillChief Operating Officer · Since at least Jun 16, 2021
Sumant RamachandraDirector · Since at least Oct 31, 2024
Veronica Sanchez BulisVP, Corporate Controller · Since at least Oct 31, 2025

Open People

Log in to ask 6ix AI your own questions about Lyell Immunopharma, Inc.